Overview

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

Status:
Completed

Trial end date:
2017-11-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men with ER positive Breast Cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Innocrin Pharmaceutical

Collaborator:

National Cancer Institute (NCI)

Treatments:

Seviteronel